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Abstract
Ovarian cancer remains difficult to treat mainly due to presentation of the disease at an advanced stage. Conditionally-
replicating adenoviruses (CRAds) are promising anti-cancer agents that selectively kill the tumor cells. The present study
evaluated the efficacy of a novel CRAd (Ad5/3-CXCR4-TIMP2) containing the CXCR4 promoter for selective viral replication in
cancer cells together with TIMP2 as a therapeutic transgene, targeting the matrix metalloproteases (MMPs) in a murine
orthotopic model of disseminated ovarian cancer. An orthotopic model of ovarian cancer was established in athymic nude
mice by intraperitonal injection of the human ovarian cancer cell line, SKOV3-Luc, expressing luciferase. Upon confirmation
of peritoneal dissemination of the cells by non-invasive imaging, mice were randomly divided into four treatment groups:
PBS, Ad-DE1-TIMP2, Ad5/3-CXCR4, and Ad5/3-CXCR4-TIMP2. All mice were imaged weekly to monitor tumor growth and
were sacrificed upon reaching any of the predefined endpoints, including high tumor burden and significant weight loss
along with clinical evidence of pain and distress. Survival analysis was performed using the Log-rank test. The median
survival for the PBS cohort was 33 days; for Ad-DE1-TIMP2, 39 days; for Ad5/3-CXCR4, 52.5 days; and for Ad5/3-CXCR4-
TIMP2, 63 days. The TIMP2-armed CRAd delayed tumor growth and significantly increased survival when compared to the
unarmed CRAd. This therapeutic effect was confirmed to be mediated through inhibition of MMP9. Results of the in vivo
study support the translational potential of Ad5/3-CXCR4-TIMP2 for treatment of human patients with advanced ovarian
cancer.
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Introduction
Ovarian cancer is the leading cause of gynecological cancer
death in the U.S. [1]. The significant morbidity and mortality in
patients with this group of tumors is attributed to the fact that
patients present only with nonspecific symptoms at the early
stages, which precludes its diagnosis [2]. The majority of the
patients are diagnosed at Stage III or beyond, where the cancer
has disseminated throughout the peritoneal cavity, which leads to
a poor prognosis. Current therapies have limitations, as the five-
year survival rate has remained unchanged at 50% over the past
four decades [3]. Thus, novel and effectively targeted therapies for
disseminated disease are urgently needed.
Conditionally replicating adenoviruses (CRAds) are a promising
new class of therapeutics, as these viruses have the potential to
selectively and self-perpetually replicate and lyse cancer cells to
eradicate the entire tumor [4]. Clinical trials with CRAds have so
far demonstrated the safety of oncolytic adenoviruses. However,
modest therapeutic efficacy with CRAds suggests further optimiza-
tion for effective clinical translation is required [5]. One strategy of
augmenting antitumor efficacy utilizes the CRAd as a platform for
the delivery of a therapeutic transgene, in addition to their oncolytic
potential [6]. To that end, we hypothesized that efficacy of a
replicating adenovirus could be improved for the treatment of
ovarian cancer by arming with a gene that acts on the host
microenvironment, as the interplay between the cancer cells and its
microenvironment has been known to modulate tumor progression
[7,8,9].
Matrix metalloproteinases (MMPs) are a diverse family of
proteases capable of degrading multiple components of the
extracellular matrix (ECM) [10]. They are one of the ideal targets
for ovarian cancer therapy, as their dysregulation has been shown
to contribute to the promotion of tumor growth, angiogenesis,
invasion and metastasis [11]. In particular, MMP-2 and MMP-9
are consistently upregulated in ovarian cancer and are associated
with poor prognosis [12,13]. Important regulator of MMPs are
their endogenous inhibitors, the tissue inhibitor of metalloprotei-
nases (TIMP), a family of small secreted proteins that act by
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To date, four mammalian TIMPs have been identified [14].
Among the TIMP family members, TIMP-2 is unique in its ability
to inhibit tumor growth and angiogenesis through pathways also
independent of MMP inhibition [15,16,17]. We hypothesized that
the production of TIMP2 from virus infected cells should bind and
inhibit excess extracellular MMPs and thereby inhibit tumor
progression through both MMP-dependent and MMP-indepen-
dent pathways.
Previously, we developed and determined the therapeutic
potential of a TIMP2-armed CRAd, Ad5/3-CXCR4-TIMP2,
for ovarian cancer therapy [18]. Transductional selectivity of the
CRAd was achieved by genetically replacing the Ad5 knob with
the Ad3 knob, which circumvents the coxsackie and adenovirus
receptor (CAR) and redirects binding to the Ad3 receptor, which is
more abundantly expressed on ovarian cancer cells [19,20]. The
CXCR4 promoter was used to mediate tumor selective replication
of the vector, as it exhibits superior activity in both established
human ovarian cancer cells and patient-derived primary tumor
tissues [18]. Further, activity of CXCR4 promoter is minimal in
the liver, the major organ known to modulate systemically
delivered adenoviral vectors [21]. The TIMP2 gene was
incorporated to inhibit tumor progression. We recently validated
in vitro that Ad5/3-CXCR4-TIMP2 produced functional TIMP2,
as indicated by the inhibition of the enzymatic degradation of
gelatin by active MMPs [18]. For the TIMP2-armed CRAd to be
efficacious, it was important that the expression of TIMP2 did not
impair viral replication or its oncolytic potency. We have recently
demonstrated that both viral replication and oncolytic potency
were not compromised in both SKOV3.ip1 and OV-4 human
ovarian cancer cells by arming with TIMP2 [18]. Further, we
demonstrated that there was selectivity in replication with the
CXCR4 promoter, as indicated by a higher level of replication in
the ovarian cancer cells, when compared to control fibroblasts.
Towards translating this virus into the clinic, we further employed
the usage of an ex vivo model system to further examine viral
replication in tumors tissues obtained from patients with
confirmed stage III and IV ovarian cancer. Results of this study
indicated a consistently high-level replication with Ad5/3-
CXCR4-TIMP2 [18]. Collectively, these data were very encour-
aging, suggesting that Ad5/3-CXCR4-TIMP2 might be effective
for the treatment of advanced ovarian cancer. In the present study,
we sought to determine the therapeutic efficacy of Ad5/3-
CXCR4-TIMP2 in a murine orthotopic model of disseminated
ovarian cancer. Tumor progression was monitored through non-
invasive in vivo imaging. Results of the present study demonstrated
a significant increase in survival following treatment with Ad5/3-
CXCR4-TIMP2, suggesting its potential for clinical translation.
Materials and Methods
Cells
The firefly luciferase–expressing ovarian adenocarcinoma cell
line SKOV3-luc was kindly provided by Dr. R. Negrin (Stanford
Medical School, Stanford, CA). The A549 human lung carcinoma
cell line was purchased from the American Type Culture
Collection (ATCC; Manassas, VA). Both cell lines were cultured
in a 1:1 mixture of Dulbecco’s modified Eagle medium (DMEM)
and Ham’s F-12 medium, supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), L-
glutamine (2 mM), penicillin (100 U/ml) and streptomycin
(100 mg/ml), at 37uC in a humidified atmosphere and at 5%
CO2. Media and supplements were purchased from Mediatech
(Herndon, VA).
Construction and production of the viruses
Ad-DE1-TIMP2 is an E1-, E3-deleted replication-deficient Ad5
vector which expresses TIMP2 under the control of the CMV
promoter [22]. Ad5/3-CXCR4, is a CRAd with the CXCR4
promoter inserted into the E1A position along with a tropism-
modified fiber, containing the Ad5 fiber shaft and tail that has had
the knob domain replaced with that of the Ad3 virus [23]. The
Ad5/3-CXCR4-TIMP2 was constructed using a full-length
human TIMP2 cDNA as described earlier [18]. The replication-
deficient adenovirus, Ad-DE1-TIMP2 was propagated in 293 cells.
The CRAds, Ad5/3-CXCR4 and Ad5/3-CXCR4-TIMP2 were
amplified in the A549 cell line. All viruses were purified by two
rounds of cesium chloride density centrifugation. The titers of viral
particles and infectious units were determined as previously
described [24].
Orthotopic ovarian cancer model and vector treatment
Female BALB/c nu/nu mice of 6 to 8 weeks of age were
obtained from the National Cancer Institute-Frederick Animal
Production Area (Frederick, MD) and quarantined for 2 weeks.
Mice were kept under pathogen-free conditions according to the
American Association for Accreditation of Laboratory Animal
Care guidelines. Animal protocols were reviewed and approved by
the Institutional Animal Care and Use Committee of the
University of Alabama at Birmingham. In vivo optical imaging
was performed at the small animal imaging core facility in the
Comprehensive Cancer Center of the University of Alabama at
Birmingham. On day 0, mice were injected intraperitoneally (i.p.)
with 5610
6 SKOV3-luc cells in 250 ml PBS and imaged for
bioluminescence to obtain baseline readings. Eight days later, mice
were reimaged to ensure the implantation of the tumors and were
then randomly divided into four groups: PBS, Ad-DE1-TIMP2,
Ad5/3-CXCR4, and Ad5/3-CXCR4-TIMP2, with n=10 per
group. Each mouse was injected i.p. with 2610
8 IU of the given
virus in 200 ml PBS, or PBS alone. All mice were imaged for
bioluminescence weekly after tumor cell injection to monitor
tumor growth. All mice were followed daily to record survival.
Survival time reflects the time required for the animals to reach
both of the following parameters. First, the clinical evidence of
pain or distress. Second, any of the pre-determined measureable
endpoints including: weight loss exceeding 15%, or weight gain
exceeding 20% of the body weight. The animal weight was
measured at day 0 and remeasured every 3 days until the end of
the experiment. Survival data were plotted on a Kaplan-Meier
curve, and different groups were compared using the Log-rank
(Mantel-Cox) test (GraphPad Prism Software v.5).
Bioluminescence imaging to detect in vivo luciferase
expression
Mice were imaged on day 0 for bioluminescent signal after
injection of SKOV3-luc cells to obtain a baseline reading of tumor
burden. Imaging was performed again before initial treatment on
day 8 and then weekly until mice were sacrificed. Briefly, 150 mg/
kg D-luciferin was injected i.p., and mice were anesthetized with
isoflurane gas anesthesia and placed in a light-tight chamber. The
photographic (gray-scale) reference image was obtained at 10 min
after D-luciferin injection, and the bioluminescent image was
collected immediately thereafter. Images were obtained with a
CCD cooled to 2120uC, using the IVIS 2100 Imaging System
(Xenogen Corp., Alameda, CA), with the field of view set at a
25 cm height. The bioluminescent images used exposures ranging
from 1 to 10 s, 1 f/stop, 4 binning, and open filter. Data
acquisition software was calibrated so that no pixels were saturated
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images were overlaid using LivingImage software. Living Image
Software (Xenogen, Alameda, CA) was also used to obtain a
pseudocolor image representing bioluminescence intensity (blue,
least intense, and red, most intense). Regions of interest were
drawn around the i.p. tumors, and the total counts (photons) were
summed for the entire tumor area. The total counts were
normalized to image acquisition time (photons/sec). Statistical
differences of tumor size among groups were assessed by the
Student’s t test. A p value of ,0.05 was considered statistically
significant. Data were presented as mean values 6SD.
Immunohistochemistry
Mice were sacrificed at high tumor burden by predetermined
parameters defined as above. At time of sacrifice, necropsies were
performed on 3 mice from each treatment group, from which
tumors and major organs were harvested and fixed into paraffin
blocks. Briefly, paraffin sections of xenografted human ovarian
tumors were deparaffinized in xylene and hydrated through
graded alcohol. Antigen retrieval was performed in citrate buffer
(pH 6.0), under steam for 20 min. Sections were cooled to room
temperature, and endogenous peroxidase was removed using 0.3%
H2O2 in methanol for 30 min and blocked with 5% BSA for
30 min. Tissue sections were then incubated with primary
antibodies overnight at 4uC. Sections were washed in Phos-
phate-Buffered Saline containing 0.05% Tween-20 (PBST) and
again incubated at room temperature with biotin-conjugated goat
anti-goat/anti-mouse secondary antibody for 2 h. After washing,
sections were incubated with streptavidin-conjugated horseradish
peroxidase for 1 h at room temperature. After another wash with
PBST, immunodetection was performed using 3,39-diaminoben-
zidine-H2O2 (Vector Labs) and counterstained with hematoxylin.
Results
Arming with TIMP2 delayed tumor growth in vivo
To evaluate the therapeutic efficacy of Ad5/3-CXCR4-TIMP2
in a clinically relevant in vivo model, we generated orthotopically
disseminated ovarian cancer by injecting female nude mice with
human SKOV3-luc cells intraperitoneally (i.p.). A luciferase-
expressing stable cell line was used to monitor the therapeutic
efficacy of treatments by noninvasive imaging in vivo. Eight days
following tumor cell administration, mice were re-imaged to
ensure implantation of the tumors and divided into four treatment
groups, with 10 mice per group. The control groups received PBS,
a replication deficient vector expressing TIMP2 (Ad-DE1-TIMP2),
or a CXCR4 promoter-regulated CRAd with a chimeric Ad5/3
fiber (Ad5/3-CXCR4). The therapeutic group received a TIMP2-
armed CXCR4 promoter based CRAd with a chimeric Ad5/3
fiber (Ad5/3-CXCR4-TIMP2) (Fig. 1). All mice were imaged after
i.p. injections of D-luciferin on a weekly basis. A panel of
representative images is shown in Fig. 2A, while quantitative
determination of bioluminescent signals is shown in Fig. 2B. Low
bioluminescent signals of SKOV3-luc cells were detected as early
as 8 days following tumor cell injection, and were relatively
consistent between the four groups. By day 22, there was
significant tumor growth in the PBS group and Ad-DE1-TIMP2
treated group. In contrast, groups treated with the CRAds had
significant inhibition in tumor growth. The group treated with the
target virus, Ad5/3-CXCR4-TIMP2, exhibited tumor regression
at day 22. By day 30, there was considerable tumor burden in the
PBS group, as mice exhibited a considerable increase in
abdominal girth and were beginning to show signs of disease
burden. In contrast, tumor growth was significantly inhibited in all
groups treated with viruses (p,0.001). By day 36, the majority of
the mice in the PBS group had died from a heavy tumor burden.
At this time point, mice treated with Ad-DE1-TIMP2, began to
display considerable tumor burden. However, both groups treated
with CRAds had significantly less bioluminescent signal
(p,0.001), indicating a slower rate of tumor development.
Furthermore, tumor burden in the cohort of mice treated with
Ad5/3-CXCR4-TIMP2, the armed CRAd, was significantly less
when compared to the tumor burden in mice treated with both
Ad5/3-CXCR4 and the unarmed CRAd (p,0.01; Fig. 2B). A
similar trend in survival following treatment with different vectors
was observed in two pilot studies with less animal numbers per
group (data not shown). Collectively, these data suggest that both
viral replication and arming with TIMP2 contributed to delaying
the onset of tumor growth.
Arming with TIMP2 increased survival
All mice were then followed for survival as shown in Fig. 3A. The
median survival time increased from 33 days, for the PBS cohort, to
39 days in the cohort injected with the nonreplicating vector
expressingTIMP2(Ad-DE1-TIMP2),thisdifferencewasstatistically
significant (p,0.03). The cohort treated with the unarmed CRAd
Figure 1. Genomic organization of armed CRAd and control viruses. Adwt300, is the wild- type Ad5 virus. Ad-DE1-TIMP2 is an E1-, E3-
deleted replication-deficient Ad5 vector which expresses TIMP2 under the control of the CMV promoter in E1. Ad5/3-CXCR4 is an unarmed CRAd with
a CXCR4 promoter in E1 to limit viral replication to the cancer cells in conjunction with a Ad5/3 modified fiber that contains the shaft and tail of Ad5
fiber and the Ad3 fiber knob. Ad5/3-CXCR4-TIMP2 is a CRAd with the CXCR4 promoter in E1, armed with TIMP2 in the E3B region and the
aforementioned F5/3 modified fiber.
doi:10.1371/journal.pone.0025131.g001
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the cohort treated with the TIMP2-armed CRAd (Ad5/3-CXCR4-
TIMP2) had a median survival time of 63 days (Fig. 3B), this
difference with also statistically significant (p,0.002). In summary,
arming with TIMP2 appears to be useful for the treatment of
disseminated ovarian cancer, as it increased survival in vivo.
TIMP2 is expressed in the tumors of armed viruses
To determine if the increased survival seen in the TIMP2-
armed CRAd when compared to the unarmed CRAd was due to
modulation of the microenvironment by TIMP2, expression of
TIMP2 was first examined in tumors excised from each treatment
group at autopsy. As seen in Fig. 4, tumors excised from groups
treated with PBS and Ad5/3-CXCR4 were negative for TIMP2
expression. Result of the immunohistochemistry indicated that in
tumors excised from cohort treated with the Ad-DE1-TIMP2 ,
TIMP2 expression was minimal and appeared limited to the
periphery of the tumor. This was not unexpected, as Ad-DE1-
TIMP2 is a non-replicating vector and was not expected to
disseminate within the tumor effectively. In contrast, tumors from
mice treated with Ad5/3-CXCR4-TIMP2 exhibited enhanced
TIMP2 staining throughout the tumor, indicating that this
oncolytic virus was effective in infecting and replicating through-
out the entire tumor.
Figure 2. Bioluminescent imaging of mice before and after treatment. Disseminated tumors were established by injecting 5610
6 SKOV3-luc
cells i.p. into female athymic nude mice on day 0. On day 8, mice were treated with either an i.p. injection of PBS, or 2610
8 IU of Ad-DE1-TIMP2, Ad5/
3-CXCR4, and Ad5/3-CXCR4-TIMP2, respectively. Bioluminescence levels were measured weekly. (A), pseudocolor image representing
bioluminescence intensity on days 8, 22, 30 and 36. (B), bioluminescence intensity from the abdominal region was quantitated and normalized,
and the mean photon counts per second for each group are shown for the given days. Data reported as the mean 6 SD for each treatment group.
*p,0.05.
doi:10.1371/journal.pone.0025131.g002
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TIMP2 is a known inhibitor of MMP2 and MMP9. Hence,
staining for active MMP2 and MMP9 was performed to
determine if the levels were affected. Results of this analysis
indicated that tumors from groups treated with PBS, Ad5/3-
CXCR4, and Ad-DE1-TIMP2, all exhibited high levels of active
MMP2. In contrast, tumors from the group treated with Ad5/3-
CXCR4-TIMP2 had very low levels of MMP2. An identical
pattern was also detected in MMP9 expression by immunohis-
tochemistry. Groups treated with PBS, Ad5/3-CXCR4, and
Ad-DE1-TIMP2, all exhibited immunoreactivity for active
MMP9. In contrast, tumors from the group treated with Ad5/
3-CXCR4-TIMP2 had very low levels of active MMP9
expression (Fig. 5). These data suggest that TIMP2 secreted
by the armed CRAd was also effective in inhibiting MMP2 and
MMP9 activities.
TIMP2-armed CRAd inhibited angiogenesis
Finally, tumors were examined for expression of CD31, a
marker for angiogenesis. Cohorts treated with PBS, Ad-DE1-
TIMP2 , and Ad5/3-CXCR4, had large diameter vessels with
minimal immunoreactivity lining the endothelial walls when
compared to the cohorts treated with Ad5/3-CXCR4-TIMP2
(Fig. 6).
Figure 3. Survival analysis. Mice were monitored for survival. Survival data are plotted on a Kaplan-Meier curve (A). Treatment with Ad5/3-CXCR4-
TIMP2 significantly enhanced survival when compared to treatment with Ad-DE1-TIMP2, Ad5/3-CXCR4, or PBS (p,0.05). (B), median survival in days
for each treatment group.
doi:10.1371/journal.pone.0025131.g003
Figure 4. TIMP-2 expression in excised epithelial ovarian
tumor. At the time of sacrifice of mice due to tumor burden, tumors
were collected from indicated treatment groups and examined for
expression of TIMP2 by immunohistochemistry.
doi:10.1371/journal.pone.0025131.g004
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The importance of the interplay between tumor cells and the
microenvironment in modulating tumor progression has long been
recognized [25]. In the pathogenesis of ovarian cancer, MMP-2
and MMP-9 are consistently upregulated [12]. Furthermore,
increased levels of these MMPs correlated negatively with survival
as they are associated with advanced stage, high-grade ascites and
positive (metastatic) lymph node [13]. These data suggest that
MMPs are valid therapeutic targets for the treatment of ovarian
cancer. A key regulator of MMPs is their endogenous inhibitors,
TIMPs. Four mammalian TIMPs have been identified thus far,
among them TIMP2 has been most extensively studied due to its
ability to inhibit tumor growth and angiogenesis by a variety of
mechanisms independent of direct MMP-inhibition [15,16,17].
TIMP2 can inhibit endothelial cell proliferation through induction
Figure 5. MMP-9 expression in excised epithelial ovarian tumor. At the time of sacrifice of mice due to tumor burden, tumors were collected
from indicated treatment groups and examined for expression of MMP-9 by immunohistochemistry.
doi:10.1371/journal.pone.0025131.g005
Figure 6. CD31 expression in excised epithelial ovarian tumor. Tumor conglomerates in the abdominal area were collected during sacrifice of
the animals from indicated treatment groups and fixed. Five mM sections of paraffin blocks of tumor tissues were stained with human CD31 antibody
to detect blood vasculature.
doi:10.1371/journal.pone.0025131.g006
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tumor growth and angiogenesis by increasing activity of mitogen-
activated protein kinase phosphatase 1 [15]. In an effort to develop
a successful CRAd geared toward the treatment of disseminated
ovarian cancer, we proposed that arming it with TIMP2 would
augment the therapeutic efficacy of the CRAd by inhibiting tumor
progression through both MMP-dependent and MMP-indepen-
dent pathways.
In our recent study, we characterized and evaluated the efficacy
of Ad5/3-CXCR4-TIMP2 in vitro. We confirmed that TIMP2
expression did not impair viral replication or oncolytic potency of
the virus. Furthermore, selective replication was achieved with the
CXCR4 promoter. Validation of Ad5/3-CXCR4-TIMP2 on
primary tumor samples from five patients with confirmed stage III
or IV ovarian cancer, revealed a consistent high level of replication
when compared to the other control viruses. Collectively, these
data suggested the potential of Ad5/3-CXCR4-TIMP2 for the
treatment of advanced ovarian cancer [18].
In the present study, we sought to determine the efficacy of
Ad5/3-CXCR4-TIMP2 in vivo. Noninvasive bioluminescent
imaging provides a powerful tool that permits longitudinal
monitoring of tumor growth in mice. Moreover, it allowed us to
use a model system that is clinically relevant. In the majority of
cases, ovarian cancer is diagnosed at an advanced stage, where the
cancer has disseminated throughout the peritoneal cavity, thus,
using a subcutaneous animal model to evaluate efficacy of
treatment, while convenient, does not reflect the natural clinical
progression of the disease. Therefore, establishing disseminated
tumors with i.p. injection of SKOV3-luc cells along with imaging
enabled us to use a clinically valid model system that can more
accurately and effectively predict the translational value of Ad5/3-
CXCR4-TIMP2. Moreover, several studies have shown sensitivity
and validity of bioluminescent imaging in i.p. tumor models
[26,27,28].
Treatment with a TIMP2-armed CRAd significantly increased
survival when compared to the unarmed CRAd, however the
increase was not robust. In the present study, virotherapy was
given with a single injection of low dose virus on day 8 after
tumor implantation. In contrast, many in vivo experiments
examining efficacy initiated treatment either before or on the
same day of tumor injection. Moreover, the viral doses used were
at least one to two logs higher and were delivered via multiple
administrations of the virus [29,30,31,32]. The main purpose of
limiting the vector dose in the present study was to establish a safe
therapeutic index. Since the nude mouse models used in the
preclinical evaluation of experimental therapies of ovarian cancer
do not have a functional immune system, increasing the vector
dose to the highest level possible to achieve a therapeutic effect
may not be appropriate for extrapolation to humans as the
highest vector dose results in activation of the immune system
causing grave side effects. However, from data in this study, it is
conceivable that with a higher dose or a multiple dosing regimen,
therapeutic efficacy could be further enhanced. One potential
downside with repeat administration of the virus is that immunity
could become a significant problem and hamper therapeutic
efficacy. Recent publication by Hemminki et al suggest that even in
the presence of significant immunity against Ad5, one could
bypass this immunity by simply using a serotype that is less
prevalent in the population, such as Ad3 and thus achieving
therapeutic efficacy without the need to increase the viral dose.
This principle could be easily applied to repeat administrations of
virus, where if immunity develops to the serotype used, then one
can simply change the backbone of the virus to a less prevalent
serotype [33]. In addition, augmentation of viral efficacy could
also be achieved by a multi-modality approach using radiation or
chemotherapy as adjuvant therapies [34,35,36]. With our current
platform of the virus targeting through Ad5/3 it is conceivable
that it could potentially infect and replicate in human immune
cells, the extent of which cannot be determined in this model, as
human Adenovirus do not replicate in mouse tissue and athymic
nude mice lack T cells. However this potential side-effect could
be mitigated by changing the tropism of the viral platform.
Perreau et al showed decreased infection of dendritic cells with
canine adenovirus serotype 2 (CAV-2) fiber knob [37]. Thus, by
switching the fiber knob from Ad5/3 to Ad-CAV2, we can
prevent the transduction of dendritic cells. Furthermore, this
allows to retain the CXCR4 promoters as it exhibits high activity
in tumor cells.
The tumor biology, the nature of peritoneal dissemination of
ovarian cancer, as well as the paradoxical roles of MMPs and
TIMPs in cancer progression further adds complexity to effective
treatment of the disease. It is well established that increased MMP-
2 and MMP-9 expression in ovarian cancer correlates negatively
with prognosis and survival [12,13,38,39,40,41]. However, the
specific roles of MMPs in ovarian cancer progression are not well
defined. Studies indicate that MMP-2 is predominately important
in early tumorgenesis by initiating metastasis through enhancing
adhesion of ovarian cancer cells to the peritoneum [42]. Thus,
therapies to block it once metastasis is established are ineffective.
However, other reports support the role of MMP-9 in tumor
growth and angiogenesis [43]. The roles of MMPs and TIMPS in
ovarian cancer are further confounded by immunohistochemical
studies looking at expression of TIMP2 in ovarian cancer tissues.
While some groups have reported low expression of TIMP2 in
primary ovarian tumors [38], others have seen increased TIMP2
expression in ovarian cancer tissues, suggesting that TIMP2
contributes to tumor progression, in part through the activation of
pro-MMP2 and inhibition of anti-tumor activities of MMPs
[39,41]. In contrast, several animal studies utilizing viral delivery
of TIMP2 have shown its utility to suppress tumor growth,
migration and metastasis in various cancer models
[44,45,46,47,48]. Collectively these studies indicate that perhaps
effects of TIMP2 on tumor promotion or suppression are
dependent on timing and the specific type of tumor. Rather than
nonspecific inhibition of MMPs, it is perhaps more useful to
specifically inhibit different MMPs during stages of tumor
progression.
Emerging data from clinical, pathological, and molecular
genetic studies suggest a new model for ovarian carcinogenesis,
where ovarian cancer is classified into two distinct groups, type I
and II [49]. Type I tumors are clinically indolent, as they are slow
growing and generally confined to the ovary at diagnosis. In
contrast, type II tumors are clinically aggressive, present at an
advanced stage and are believed to arise de novo, as precursor
lesions have not been identified. The type II tumors, accounting
for 70% of ovarian cancer, are characterized by mutations of
TP53 in 80% of the cases. This new data suggest that p53 could
potentially be a therapeutic target to arm the virus for ovarian
cancer therapy. CRAds armed with p53 have been shown in vitro
to enhance oncolysis in cervical cancer [50] and a variety of other
cancer cell lines [51]. Another potential therapeutic target is
CXCR4, the only chemokine receptor found to be expressed on
ovarian cancer [52]. The ligand for CXCR4 is CXCL12, which
can stimulate ovarian cancer cells migration in vitro. CXCL12 is
present in ascites and is expressed by peritoneal mesothelial cells,
thus explaining that in part, migration and attachment of ovarian
cancer cells to the peritoneum are facilitated by CXCL12–
CXCR4 interactions. Ablating this interaction with a CXCR4
Gene Therapy for Ovarian Cancer
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vitro [53].
While there is some literature on CRAds for ovarian cancer
therapy [23,29,30,31,32,34,54,55,56], there is very limited re-
search on the usage of an armed CRAd. We report here for the
first time, evaluation of a CRAd delivering a noncytotoxic gene for
the treatment of disseminated ovarian cancer. It is conceivable
that with further refinements in terms of vector targeting,
therapeutic dose, multiple dosing schedule and usage with
adjuvant chemotherapy or radiotherapy, therapeutic efficacy can
be significantly enhanced while minimizing deleterious effect on
the immune system.
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